Literature DB >> 8730268

Local and systemic chemotherapy in the management of periodontal disease: an opinion and review of the concept.

M Addy1, P Renton-Harper.   

Abstract

Periodontal disease appears to arise from the interaction of pathogenic bacteria with a susceptible host. The main aims of disease management have been to establish a high standard of oral hygiene and to professionally and thoroughly debride the root surface Chemical agents could be considered for both aspects of management. Chemoprevention using supragingivally delivered agents such as chlorhexidine may be questioned for value in the pre-treatment hygiene phase but have well-established efficacy immediately preoperatively and during the post-operative weeks. Long-term maintenance use of chlorhexidine is problematic due to local side effects. Antiplaque toothpastes show modest benefits to gingivitis but are not proven to prevent recurrence of periodontitis. Chemotherapy may be directed at subgingival plaque, using antimicrobials, or at the host response using anti-inflammatory agents. Antimicrobials can be locally or systemically delivered. In most cases antimicrobial chemotherapy should be considered adjunctive to mechanical debridement. The advantages of local and systemic chemotherapy must be balanced against the disadvantages and potential side effects of agents. Antimicrobial chemotherapy offers little or no benefit to the treatment of most chronic adult periodontitis patients and should be reserved for the more rapid or refractory types of disease, and after the debridement phase. Despite the large number of studies there are insufficient comparative data to support any one local delivery system or systemic regimen as superior to another. Systemic versus local antimicrobials have not been compared to date. Host response modifying drugs such as non-steriodal anti-inflammatory drugs (NSAIDS) offer the potential to reduce breakdown and promote healing, including bone regeneration. However until more data are available, NSAIDs should not be used in the management of chronic periodontal diseases, there being no specific agent(s) or regimen established for use. Chemotherapy has an important place in the management of chronic periodontal diseases but routine use must be considered as an over prescription of these valuable agents.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730268     DOI: 10.1111/j.1365-2842.1996.tb00845.x

Source DB:  PubMed          Journal:  J Oral Rehabil        ISSN: 0305-182X            Impact factor:   3.837


  3 in total

1.  Bioerodible injectable poly(ortho ester) for tetracycline controlled delivery to periodontal pockets: preliminary trial in humans.

Authors:  K Schwach-Abdellaoui; P J Loup; N Vivien-Castioni; A Mombelli; P Baehni; J Barr; J Heller; R Gurny
Journal:  AAPS PharmSci       Date:  2002

2.  Periodontal conditions, oral Candida albicans and salivary proteins in type 2 diabetic subjects with emphasis on gender.

Authors:  Fawad Javed; Lena Klingspor; Ulf Sundin; Mohammad Altamash; Björn Klinge; Per-Erik Engström
Journal:  BMC Oral Health       Date:  2009-05-12       Impact factor: 2.757

3.  Influence of Tooth-Brushing on Early Healing after Access Flap Surgery: A Randomized Controlled Preliminary Study.

Authors:  Carlo Bertoldi; Luigi Generali; Pierpaolo Cortellini; Michele Lalla; Sofia Luppi; Aldo Tomasi; Davide Zaffe; Roberta Salvatori; Stefania Bergamini
Journal:  Materials (Basel)       Date:  2021-05-29       Impact factor: 3.623

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.